Samidorphan
Lybalvi (samidorphan) is a small molecule pharmaceutical. Samidorphan was first approved as Lybalvi on 2021-05-28. It is known to target delta-type opioid receptor, kappa-type opioid receptor, and mu-type opioid receptor. Lybalvi's patents are valid until 2032-02-13 (FDA).
| Trade Name | Lybalvi |
|---|---|
| Common Name | Samidorphan |
| Indication | |
| Drug Class | Narcotic antagonists/agonists (morphinan derivatives) |
